Flash Finance

Brawn Biotech Ltd530207Corporate

Pharmaceuticals Latest results: Jun 2023 3 quarters of data
Consolidated Standalone
₹22.90
MCap ₹7 Cr
Brawn Biotech Ltd — Stock analysis & AI research Brawn Biotech Ltd — Live exchange announcements
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹0 Cr
Sales · Jun 2023
+0.0% YoY
₹-0 Cr
Operating Profit · Jun 2023
-233.3% YoY
-33.3%
OPM % · Jun 2023
-233.2% YoY
₹-0 Cr
Net Profit · Jun 2023
-300.0% YoY
₹-0.13
EPS · Jun 2023
-285.7% YoY

📝 Brawn Biotech Ltd — results explained

Quarter ended June 2023 (Q1 FY24)

Brawn Biotech Ltd reported revenue of ₹0 crore for the quarter ended June 2023 (Q1 FY24), flat from ₹0 crore in the same quarter last year, and flat sequentially over the March 2023 quarter.

The company reported a net loss of ₹0 crore, against a net profit of ₹0 crore in the same quarter last year. Earnings per share (EPS) came in at ₹-0.13.

Operating profit stood at ₹-0 crore — an operating margin (OPM) of -33.3%, compared with 25.0% in the year-ago quarter.

Valuation snapshot

At the current price of ₹22.90, 530207 has a market capitalisation of ₹7 crore.

Within the Pharmaceuticals industry, it is the 25th-largest of the 82 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 52.94%, domestic institutional investors (DIIs) 0.35%, public shareholders 46.72% of Brawn Biotech Ltd.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹7 Cr
Current Price ?
₹22.9
P/E ?
N/A
Industry P/E ?
22.40
P/B ?
1.58
P/S ?
N/A
P/FCF ?
85.87
Enterprise Value ?
₹7 Cr
EV/EBITDA ?
N/A
PEG ?
N/A
Earnings Yield ?
N/A
Dividend Yield ?
0.00%
Profitability & Returns
Sales (TTM) ?
N/A
OPM ?
N/A
Profit after tax (TTM) ?
N/A
EPS (TTM) ?
N/A
ROCE ?
0.0%
ROE ?
N/A
ROA ?
N/A
Growth
Sales — latest qtr ?
₹0 Cr
PAT — latest qtr ?
₹-0 Cr
YoY qtr sales growth ?
0.0%
YoY qtr profit growth ?
-300.0%
Sales growth (3y) ?
N/A
Sales growth (5y) ?
N/A
Profit growth (3y) ?
N/A
Profit growth (5y) ?
N/A
Financial Health
Debt ?
₹0 Cr
Debt to Equity ?
0.00
Interest Coverage ?
N/A
Current Ratio ?
N/A
Ownership
Promoter holding ?
52.94%
Change in promoter holding ?
-0.72%
Pledged percentage ?
N/A
Market
Return 3 months ?
14.8%
Return 6 months ?
13.9%

🗓️ Quarterly results (3 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Jun 2022Mar 2023Jun 2023 YoY % QoQ %
Sales 000 +0.0% +0.0%
Operating Profit 00-0 -233.3% -200.0%
Other Income 000 — -100.0%
Interest 000 — —
Depreciation 000 — —
Profit Before Tax 00-0 -233.3% -114.8%
Net Profit 00-0 -300.0% -117.4%
EPS 0.070.77-0.13 -285.7% -116.9%
OPM % 25.0% 33.3% -33.3% -233.2% -200.0%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 3.003.003.003.00 +0.0%
Reserves 3.312.060.361.34 +272.2%
Borrowings 0.000.000.000.00 —
Other Liabilities 8.229.5317.1316.52 -3.6%
Total Liabilities 14.5314.5920.4920.86 +1.8%
Fixed Assets 0.370.330.460.36 -21.7%
CWIP 0.000.000.000.00 —
Investments 0.000.000.000.00 —
Other Assets 14.1614.2620.0320.50 +2.3%
Total Assets 14.5314.5920.4920.86 +1.8%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 0.32-0.030.050.11 +120.0%
Cash from Investing Activity -0.10-0.01-0.24-0.03 +87.5%
Cash from Financing Activity -0.010.000.000.00 —
Net Cash Flow 0.21-0.04-0.200.08 +140.0%
Free Cash Flow 0.22-0.04-0.190.08 +142.1%
CFO/OP -103%2%-3%-33% -1000.0%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 87.3585.8892.4776.31 -17.5%
Inventory Days 91.20153.02320.33253.06 -21.0%
Days Payable 123.19144.12252.10362.48 +43.8%
Cash Conversion Cycle 55.3694.78160.70-33.11 -120.6%
Working Capital Days 80.62137.90216.4035.90 -83.4%
ROCE % -5.91%-25.86%-42.52%0.00% +100.0%

👥 Shareholding (latest 4 periods)

Metric Sep 2025Dec 2025Mar 2026Jun 2026 % Chg
Promoters 53.66%53.39%52.94%52.94% +0.0%
DIIs 0.35%0.35%0.35%0.35% +0.0%
Public 45.99%46.27%46.72%46.72% +0.0%
No. of Shareholders 3,9583,4443,3033,284 -0.6%

⚖️ Peer comparison

Industry: Pharmaceuticals · top 25 of 82 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUDEEPPHRM Sudeep Pharma ₹1,033.30 11,671 63.3 675 184 34.6% 27.3% — — 26.6% 30.9%
2 SPARC Sun Pharma ₹185.08 6,006 3.8 1,909 1,584 84.7% 83.0% 2512.3% 553.9% 314.1% 59.9%
3 GUJTHEM Gujarat Themis ₹412.60 5,370 92.3 173 48 47.3% 27.8% 8.6% -6.1% 21.6% 23.0%
4 539997 Kwality Pharmaceuticals ₹2,652.10 3,525 34.0 553 81 24.4% 14.6% 35.7% 71.8% 46.3% 113.5%
5 524632 Shukra Pharmaceuticals ₹80.95 2,403 99.9 75 36 65.0% 48.2% 74.0% 130.1% 336.4% 1359.2%
6 FERMENTA Fermenta Biotech ₹475.00 1,362 21.4 501 64 18.9% 12.7% — — -17.9% -30.6%
7 506414 Fermenta Biotech ₹552.60 1,313 27.2 511 59 17.6% 11.5% 11.9% -6.6% -10.4% -56.7%
8 AHCL Anlon Healthcare ₹20.20 1,074 — — — — — — — 163.0% 133.3%
9 541096 Bharat Parenterals ₹1,525.00 1,062 — 323 -30 3.3% -9.3% 1.5% 37.5% -19.2% -309.6%
10 540737 Shree Ganesh ₹796.30 855 66.2 99 15 31.4% 15.6% 0.7% -23.0% -41.8% -67.5%
11 AMANTA Amanta Healthcare ₹197.75 768 52.5 291 15 20.4% 5.0% — — 5.4% -5.6%
12 539730 Fredun Pharmaceuticals ₹827.85 611 10.3 747 44 14.7% 5.9% 40.1% 90.0% 90.2% 88.1%
13 500422 Transchem Ltd-$ ₹38.00 474 10.8 — 4 — — -100.0% -17.8% -100.0% 186.3%
14 HALEOSLABS Haleos Labs ₹1,525.00 461 21.0 324 15 12.6% 4.7% -3.2% -4.9% -11.6% -58.0%
15 524731 Jenburkt Pharmaceuticals ₹865.75 404 11.6 170 33 23.6% 19.4% 11.8% 6.1% -1.4% -26.4%
16 543616 Trident Lifeline ₹279.85 364 14.0 134 24 24.6% 17.9% — — 42.6% 44.2%
17 512600 Astal Laboratories ₹75.00 308 32.3 170 10 8.8% 5.7% 142.9% -9.0% 56.0% 77.4%
18 524828 BDH Industries ₹336.80 300 16.6 100 12 15.3% 11.7% 44.3% 16.6% 20.2% 48.8%
19 500009 Ambalal Sarabhai ₹38.73 297 21.9 206 14 7.1% 6.6% 3.1% 261.1% 8.0% -51.6%
20 532039 Zenotech Laboratories ₹64.90 263 — 45 -3 17.0% -5.6% 1.3% -119.2% 10.1% -146.0%
21 531739 Gennex Laboratories ₹13.87 255 19.0 183 21 14.4% 11.3% 24.9% 15.5% 16.6% -6.9%
22 524790 Everest Organics ₹159.20 252 29.4 191 5 10.3% 2.8% 23.0% 527.7% -10.0% -21.1%
23 530163 Kerala Ayurveda ₹310.20 225 — 125 -26 -14.9% -20.8% 9.0% -16.8% -21.3% -477.8%
24 531569 Sanjivani Paranteral ₹199.95 214 32.7 66 7 15.3% 11.3% -7.6% -14.4% 8.8% 32.7%
25 530207 Brawn Biotech ₹24.80 7 8.7 17 1 -2.7% 5.0% 26.2% 152.5% 4.8% -35.7%
❓ Frequently asked questions
What was Brawn Biotech Ltd's revenue in Q1 FY24?
Brawn Biotech Ltd reported revenue of ₹0 crore for the quarter ended June 2023 (Q1 FY24), flat from ₹0 crore in the same quarter last year, and flat sequentially over the March 2023 quarter.
What was Brawn Biotech Ltd's net profit in Q1 FY24?
The company reported a net loss of ₹0 crore, against a net profit of ₹0 crore in the same quarter last year. Earnings per share (EPS) came in at ₹-0.13.
What is 530207's market capitalisation and P/E ratio?
At the current price of ₹22.90, 530207 has a market capitalisation of ₹7 crore.
Who owns Brawn Biotech Ltd? (shareholding pattern)
As of Jun 2026, promoters held 52.94%, domestic institutional investors (DIIs) 0.35%, public shareholders 46.72% of Brawn Biotech Ltd.
TTM ends N/A. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI